Acadian Asset Management
CLDX icon

Acadian Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Acadian Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Buy
+2,781
New +$89.8K ﹤0.01% 1749
2024
Q4 		– Sell
-4,591
Closed -$156K – 1709
2024
Q3 		$156K Buy
+4,591
New +$175K ﹤0.01% 1450
2020
Q3 		– Sell
-228,015
Closed -$2.96M – 2192
2020
Q2 		$2.96M Sell
228,015
-70,634
-24% -$313K 0.01% 623
2020
Q1 		$496K Buy
298,649
+50,583
+20% +$114K ﹤0.01% 962
2019
Q4 		$553K Sell
248,066
-8,242
-3% -$19.1K ﹤0.01% 1046
2019
Q3 		$547K Sell
256,308
-11,249
-4% -$26K ﹤0.01% 1062
2019
Q2 		$718K Buy
267,557
+120,519
+82% +$409K ﹤0.01% 899
2019
Q1 		$723K Buy
147,038
+55,480
+61% +$292K ﹤0.01% 1007
2018
Q4 		$272K Buy
91,558
+19,152
+26% +$94.1K ﹤0.01% 1051
2018
Q3 		$490K Sell
72,406
-4,786
-6% -$33.5K ﹤0.01% 884
2018
Q2 		$583K Buy
77,192
+61,058
+378% +$816K ﹤0.01% 859
2018
Q1 		$563K Buy
+16,134
New +$625K ﹤0.01% 833

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management's CLDX Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 2,781 shares worth $102K. The stake represents ﹤0.01% of the portfolio and ranks #1749 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in CLDX as recently as Q3 2024.

Acadian Asset Management first reported a position in CLDX in Q1 2018 and has held it in 12 quarters since. The position peaked at $2.96M in Q2 2020. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Acadian Asset Management held 2,781 shares of Celldex Therapeutics worth $102K as of Q2 2026.
  • Celldex Therapeutics was a new Acadian Asset Management position in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1749 holding.
  • Acadian Asset Management first reported a position in Celldex Therapeutics in Q1 2018 and has held it in 12 quarters since.
  • Acadian Asset Management's Celldex Therapeutics position peaked at $2.96M in Q2 2020.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.